Friday 21 May 2021

PDS Bio still the story - another out-sized gain of just under 15% on a flat day


Smaller Covid Vaccine Stocks do better than the bigger ones. PDS Bio is still the main story with a gain of 14.6%. Without PDS Bio, there would be a loss of 0.8% on the overall average. With PDS Bio, the loss is reduced to 0.2% on an overall average basis.

There were 15 stocks that lost ground with 9 gainers. 

Immunity Bio dropped just under 7%. No other stock gained or lost more than 5%.

 

No comments:

Post a Comment